Related Links

  • Alize Pharma
  • Elsevier Ltd is not responsible for the content of external websites.


Alizé Pharma signs research collaboration and license option agreement with Lilly

Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of type II diabetes.

Alizé Pharma, a group of companies developing therapeutics for metabolic diseases and cancer, announced today that Alizé Pharma SAS has entered into a research collaboration and license option agreement with Eli Lilly and Company regarding Alizé Pharma's AZP-01 programme, a programme focused on the development of unacylated ghrelin (UAG) agonists for the treatment of type II diabetes.

Under the terms of the agreement, Lilly will pay an undisclosed upfront fee and both companies will collaborate on Alizé's AZP-01 project. In return, Lilly will be granted an exclusive option to license the programme according to predefined terms. Other terms of the deal were not disclosed.

Alizé's AZP-01 programme aims to develop UAG agonists, a new potential therapeutic class for the treatment of type II diabetes. Available preclinical and preliminary clinical data suggest that UAG and its analogues have therapeutic potential in diabetes through a novel mechanism of action that includes glucose- and lipid-lowering effects, a trophic effect on beta cells, as well as insulin-sensitizing actions. Thus, UAG and its analogues might have the potential not only to control the disease but also to have a positive impact on other cardiovascular risk factors such as obesity, dyslipidemia and impaired vascular remodeling.

‘We are very pleased with this first agreement with Lilly, a recognized leader in the field of diabetes,’ said Alizé Pharma president and founder, Thierry Abribat. ‘This collaboration will put our UAG program on the best possible track. It gives us access to Lilly's proven expertise in developing first-in-class molecules, while leveraging our resources and remaining totally in line with our business plan.’

‘We have been impressed with the work performed thus far by Alizé Pharma and its academic partners on this AZP-01 program,’ said Philip J Larsen, chief scientific officer for diabetes research at Lilly. ‘As part of our commitment to remain leaders in diabetes care, we look forward to launching this research collaboration with Alizé on this promising new target, and working together to validate the therapeutic potential of drugs in this class.’

Share this article

More services


This article is featured in:
Companies and People  •  Pharmacology/ Therapeutics


Comment on this article

You must be registered and logged in to leave a comment about this article.